Abstract：
OBJECTIVE: This study was undertaken to evaluate the outcome of curative liver resection, (LR) of Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma (BCLC-C HCC) after tyrosine kinase inhibitors (TKIs) became approved as a treatment option for recurrent lesions.
METHODS: Sixty-seven patients with BCLC-C HCC who underwent curative LR were enrolled in this study. The patients were classified into two groups according to whether LR was performed before (n = 24) or after (n = 43) TKI approval (\"beforeTKI\" and \"afterTKI\" group, respectively).
RESULTS: There was no difference in the median disease-free survival time after LR between the beforeTKI and afterTKI groups (5.6 and 7.1 months, respectively; p = 0.435). However, the median survival time after LR was longer in the afterTKI than beforeTKI group (42.7 and 14.9 months, respectively; p = 0.022). Univariate and multivariate analyses showed that the date of LR was the only independent factor affecting postresection survival. When the patients were limited to those with recurrence, there were no differences in the recurrence pattern or progression of HCC at the time of recurrence between the two groups. The only difference in the treatment distribution was the administration of TKIs (14 of 34 patients in afterTKI group and only 1 of 19 patients in beforeTKI group, p < 0.001).
CONCLUSIONS: These data suggest that TKI therapy for recurrent BCLC-C HCC is associated with improved overall survival. Thus, LR could be a promising option for BCLC-C HCC in the current era of TKI therapy.
METHODS: Sixty-seven patients with BCLC-C HCC who underwent curative LR were enrolled in this study. The patients were classified into two groups according to whether LR was performed before (n = 24) or after (n = 43) TKI approval (\"beforeTKI\" and \"afterTKI\" group, respectively).
RESULTS: There was no difference in the median disease-free survival time after LR between the beforeTKI and afterTKI groups (5.6 and 7.1 months, respectively; p = 0.435). However, the median survival time after LR was longer in the afterTKI than beforeTKI group (42.7 and 14.9 months, respectively; p = 0.022). Univariate and multivariate analyses showed that the date of LR was the only independent factor affecting postresection survival. When the patients were limited to those with recurrence, there were no differences in the recurrence pattern or progression of HCC at the time of recurrence between the two groups. The only difference in the treatment distribution was the administration of TKIs (14 of 34 patients in afterTKI group and only 1 of 19 patients in beforeTKI group, p < 0.001).
CONCLUSIONS: These data suggest that TKI therapy for recurrent BCLC-C HCC is associated with improved overall survival. Thus, LR could be a promising option for BCLC-C HCC in the current era of TKI therapy.
摘要：
目的：本研究旨在评估根治性肝切除术的结果，（LR）的巴塞罗那临床肝癌C期肝细胞癌（BCLC-CHCC）后，酪氨酸激酶抑制剂（TKIs）被批准为复发性病变的治疗选择。
方法：本研究纳入了67例BCLC-CHCC患者，这些患者接受了治疗性LR。根据是否在TKI批准之前（n=24）或之后（n=43）进行LR将患者分为两组（\“beforeTKI\”和\“afterTKI\”组，分别)。
结果：在TKI之前和TKI之后，LR后的中位无病生存时间没有差异（5.6和7.1个月，分别为；p=0.435)。然而,TKI后LR后的中位生存时间长于TKI前（42.7个月和14.9个月，分别为；p=0.022)。单变量和多变量分析表明，LR的日期是影响切除术后生存的唯一独立因素。当患者仅限于复发患者时，两组在复发时HCC的复发模式或进展无差异.治疗分布的唯一差异是TKIs的给药（TKI后34例患者中有14例，TKI前19例患者中只有1例，p<0.001)。
结论：这些数据表明TKI治疗复发性BCLC-CHCC与改善总生存期相关。因此，在当前TKI治疗时代，LR可能是BCLC-CHCC的有希望的选择。
方法：本研究纳入了67例BCLC-CHCC患者，这些患者接受了治疗性LR。根据是否在TKI批准之前（n=24）或之后（n=43）进行LR将患者分为两组（\“beforeTKI\”和\“afterTKI\”组，分别)。
结果：在TKI之前和TKI之后，LR后的中位无病生存时间没有差异（5.6和7.1个月，分别为；p=0.435)。然而,TKI后LR后的中位生存时间长于TKI前（42.7个月和14.9个月，分别为；p=0.022)。单变量和多变量分析表明，LR的日期是影响切除术后生存的唯一独立因素。当患者仅限于复发患者时，两组在复发时HCC的复发模式或进展无差异.治疗分布的唯一差异是TKIs的给药（TKI后34例患者中有14例，TKI前19例患者中只有1例，p<0.001)。
结论：这些数据表明TKI治疗复发性BCLC-CHCC与改善总生存期相关。因此，在当前TKI治疗时代，LR可能是BCLC-CHCC的有希望的选择。
